osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
#asco23: patients with resected, egfr-mutated, stage ib to iiia nsclc were randomly assigned to receive adjuvant osimertinib or placebo for 3 years. the 5-year overall survival was 88% with osimertinib &amp; 78% with placebo. full results of the adaura trial: 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.